Author

F. Zammarchi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1

Frequent Co-Authors

P. H. van Berkel· 3 shared A. Stathis· 2 shared C. Tarantelli· 2 shared E. Gaudio· 2 shared E. Zucca· 2 shared F. Bertoni· 2 shared F. Spriano· 2 shared G. Golino· 2 shared

Activity by Year

2023-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

P. H. van Berkel

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma

A. K. Weiner, A. B. Radaoui, M. Tsang, D. Martinez, S. Sidoli, K. L. Conkrite, A. Delaidelli, A. Modi, J. L. Rokita, K. Patel, M. V. Lane, B. Zhang, C. Zhong, B. Ennis, D. P. Miller, , S. J. Diskin

This study identifies DLK1 as a potential immunotherapeutic target in neuroblastoma through integrative proteomic, transcriptomic, and epigenomic analysis.

bioRxiv · Dec 6, 2023 · PreprintCancer Biology

Targeting CD19-positive lymphomas with the antibody-drug conjugate (ADC) loncastuximab tesirine: preclinical evidence as single agent and as combinatorial approach

C. Tarantelli, D. Wald, N. Munz, F. Spriano, A. Bruscaggin, E. Cannas, L. Cascione, E. Gaudio, A. J. Arribas, S. Manjappa, G. Golino, L. Scalise, E. Zucca, A. Stathis, P. H. Van Berkel, , F. Bertoni

This study evaluates the efficacy of the anti-CD19 ADC loncastuximab tesirine as a single agent and in combination with other therapies against lymphomas.

bioRxiv · Aug 17, 2023 · PreprintCancer Biology

Targeting CD25-positive lymphoma cells with the antibody-drug conjugate camidanlumab tesirine as single agent or in combination with targeted agents

F. Spriano, C. Tarantelli, L. Cascione, E. Gaudio, G. Golino, L. Scalise, E. Zucca, A. Stathis, P. H. Van Berkel, F. Zammarchi, F. Bertoni

This study evaluates the anti-lymphoma activity of camidanlumab tesirine as a single agent and in combination with targeted agents in various lymphoma cell lines.

bioRxiv · Jul 2, 2023Cancer Biology